p38 mitogen-activated protein kinase contributes to the diminished aortic contraction by endothelin-1 in DOCA-salt hypertensive rats

Hypertension. 2004 May;43(5):1086-91. doi: 10.1161/01.HYP.0000125995.85427.fd. Epub 2004 Mar 29.

Abstract

We investigated whether the diminished contractile responsiveness to endothelin-1 (ET-1) is associated with the altered activation of mitogen-activated protein kinase (MAPK) in aortic smooth muscles from deoxycorticosterone acetate (DOCA)-salt hypertensive rats. ET-1 dose-dependently increased contractions in aortic smooth muscle strips, and the contractions were significantly attenuated in tissues from DOCA-salt hypertensive rats compared with those from sham-operated rats. The phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 was elevated by ET-1, with the magnitude and time-course being similar between strips. Although ET-1 also increased the phosphorylation of p38 MAPK in both strips, the increment was markedly lower in the strips from DOCA-salt hypertensive rats compared with sham-operated controls. 5-hydroxytryptamine (5-HT) increased vascular contraction and phosphorylation of both MAPK isoforms; these were greater in DOCA-salt hypertensive rats than in sham-operated rats. ET-1 also increased the phosphorylation of caldesmon, an actin-binding protein, in sham-operated and DOCA-salt hypertensive rats. However, the increment was markedly lower in the strips from DOCA-salt hypertensive rats compared with sham-operated controls. The phosphorylation of MAPK isoforms and caldesmon elevated by ET-1 was inhibited by PD098059, an inhibitor of ERK1/2 kinase, and SB203580, an inhibitor of p38 MAPK, respectively. These results suggest that ET-1 and 5-HT induce contraction by activating the MAPK pathway in rat aortic smooth muscle and that the diminished responsiveness to ET-1 in the DOCA-salt hypertensive rat may be, in part, mediated by the decrease of caldesmon phosphorylation after the decreased activation of p38 MAPK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects*
  • Aorta / enzymology
  • Calmodulin-Binding Proteins / metabolism
  • Desoxycorticosterone / toxicity
  • Endothelin-1 / pharmacology*
  • Flavonoids / pharmacology
  • Hypertension / chemically induced
  • Hypertension / enzymology*
  • Hypertension / physiopathology
  • Imidazoles / pharmacology
  • Isoenzymes / metabolism
  • Male
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / physiology
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / deficiency
  • Mitogen-Activated Protein Kinases / physiology*
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / physiopathology
  • Phosphorylation / drug effects
  • Protein Processing, Post-Translational / drug effects
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin / pharmacology
  • Sodium Chloride, Dietary / toxicity
  • Vasoconstriction / drug effects*
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Calmodulin-Binding Proteins
  • Endothelin-1
  • Flavonoids
  • Imidazoles
  • Isoenzymes
  • Pyridines
  • Sodium Chloride, Dietary
  • Serotonin
  • Desoxycorticosterone
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one